Allogene Therapeutics
ALLO
About: Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
Employees: 361
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
38% more call options, than puts
Call options by funds: $223K | Put options by funds: $162K
13% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 46
0% more funds holding in top 10
Funds holding in top 10: 6 [Q1] → 6 (+0) [Q2]
6.69% less ownership
Funds ownership: 90.63% [Q1] → 83.94% (-6.69%) [Q2]
7% less funds holding
Funds holding: 169 [Q1] → 157 (-12) [Q2]
31% less capital invested
Capital invested by funds: $301M [Q1] → $208M (-$93.6M) [Q2]
37% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 27
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
|
Oppenheimer
Mark Breidenbach
|
$7
|
Outperform
Maintained
|
1 Aug 2025 |
Financial journalist opinion
Based on 3 articles about ALLO published over the past 30 days
